COVID-19 hit the SCS market hard in Q220 as shutdowns and widespread procedure cancellations led to a dramatic decline in SCS revenues.
COVID-19 clobbered the SCS market in Q220 as shutdowns and widespread procedure cancellations led to a dramatic decline in SCS revenues, with the biggest impact in April across all geographies. For Q220, WW SCS revenues tumbled down -38.1% vs Q219, and US SCS revenue dropped by -37.7% YoY according to SmartTRAK Financial Dashboard.
Among the many topics covered in the comprehensive Q220 SCS Market Recap* are:
- Complete Q220 Spinal Cord Stimulation Market Overview
- Medtronic: Making Inroads with DTM SCS
- Boston Scientific: Seeing Solid Recovery
- Abbott: Connectivity as a Competitive Edge
- Latest Innovation
- Nevro Capturing Share
- Omnia Gaining Traction
- PDN/NSRBP Update
- Selected Regulatory News
Given the disruption from COVID-19, YTD revenues may provide more visibility into what’s going on in the SCS market in terms of shares and share gain. SmartTRAK Financial Dashboard shows H120 SCS market share has been relatively stable for all the players YoY. However, NVRO has been capturing a small amount of share from each player in both the US and WW and appears to have ...
Read the entire Q220 SCS Market Recap including news, data, charts, company revenues and analysis*
*The entire article and the links can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click the button below.